Next Article in Journal
Natural Flavonoids for the Prevention of Sarcopenia: Therapeutic Potential and Mechanisms
Previous Article in Journal
APTIMA mRNA vs. DNA-Based HPV Assays: Analytical Performance Insights from a Resource-Limited South African Setting
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 26
Issue 15
10.3390/ijms26157456
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Polymorphic Variants of Selected Genes Regulating Bile Acid Homeostasis in Women with Intrahepatic Cholestasis of Pregnancy

by
Krzysztof Piątek
1,
Grażyna Kurzawińska
2,
Marcin Ożarowski
3,*,
Piotr Józef Olbromski
4,
Adam Kamiński
5,
Maciej Brązert
6,
Tomasz M. Karpiński
7,*,
Wiesław Markwitz
8 and
Agnieszka Seremak-Mrozikiewicz
2,8
1
Department of Gynecology and Obstetrics, University of Zielona Gora, Licealna 9, 65-417 Zielona Gora, Poland
2
Laboratory of Molecular Biology, Department of Perinatology, Poznan University of Medical Sciences, Polna 33, 60-535 Poznan, Poland
3
Department of Biotechnology, Institute of Natural Fibres and Medicinal Plants—National Research Institute, Wojska Polskiego 71B, 60-630 Poznan, Poland
4
Clinic of Operational Gynecology, Poznan University of Medical Sciences, Polna 33, 60-535 Poznan, Poland
5
Department of Orthopedics and Traumatology, Independent Public Clinical Hospital No. 1, Pomeranian Medical University in Szczecin, Unii Lubelskiej 1, 71-252 Szczecin, Poland
6
Department of Diagnostics and Treatment of Infertility, Poznan University of Medical Sciences, Polna 33, 60-535 Poznan, Poland
7
Chair and Department of Medical Microbiology, Poznan University of Medical Sciences, Rokietnicka 10, 60-806 Poznań, Poland
8
Department of Perinatology, Poznan University of Medical Sciences, Polna 33, 60-535 Poznan, Poland
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(15), 7456; https://doi.org/10.3390/ijms26157456
Submission received: 25 May 2025 / Revised: 29 July 2025 / Accepted: 29 July 2025 / Published: 1 August 2025
(This article belongs to the Section Molecular Genetics and Genomics)
Browse Figures
Versions Notes

Abstract

Intrahepatic cholestasis of pregnancy (ICP) is characterized by the onset of pruritus and elevated serum transaminases and bile acids (BA). The key enzyme in BA synthesis is CYP7A1, and its functions are regulated by various nuclear receptors. The goal of this study is to evaluate the association between CYP7A1, NR1H1, RXRA, and PPARA gene variants and risk of ICP. Five single nucleotide variants (SNVs), rs3808607 (CYP7A1), rs56163822 (NR1H4), rs1800206 (PPARA), rs749759, and rs11381416 (NR2B1), were genotyped in a group of 96 ICP and 211 controls. The T allele of the CYP7A1 (rs3808607) variant may be a protective factor against ICP risk (OR = 0.697, 95% CI: 0.495–0.981, p = 0.038). Genetic model analysis showed that rs3808607 was associated with decreased risk of ICP under dominant (OR = 0.55, 95% CI: 0.32–3.16, p = 0.032, AIC = 380.9) and log-additive models (OR = 0.71, 95% CI: 0.51–1.00, p = 0.046, AIC = 381.4). The A insertion in the rs11381416 NR2B1 variant was associated with the degree of elevation in the liver function tests TBA (34.3 vs. 18.8 μmol/L, p = 0.002), ALT (397.0 vs. 213.0 IU/L, p = 0.017), and AST (186.0 vs. 114.4 IU/L, p = 0.032) in ICP women. Results indicate an association between the CYP7A1 rs3808607 and the risk of ICP and the association of the rs11381416 of the NR2B1 receptor with higher values of liver function tests in women with ICP. A better understanding of the cooperation of proteins involved in BA metabolism may have important therapeutic implications in ICP and other hepatobiliary diseases.

1. Introduction

ICP (Intrahepatic cholestasis of pregnancy) is a liver disorder that occurs in the late second and early third trimester of pregnancy. Although ICP is associated with relatively mild complications for the mother, such as intense itching and liver dysfunction, it may increase the risk of later hepatobiliary disease. However, the condition carries serious risks for the fetus, including preterm labor, meconium-stained amniotic fluid, and stillbirth [1,2]. The study by Floreani et al. [3] showed an increased risk of preterm birth (p < 0.001) and a higher rate of cesarean delivery (p = 0.05) [3]. A prospective cohort study from Sweden showed that the probability of fetal complications (spontaneous preterm deliveries, asphyxial events, and meconium staining of amniotic fluid, placenta, and membranes) increased by 1–2% per additional μmol/L of serum bile acids. However, the researchers emphasize that the increased risk to the fetus applies to patients with ICP whose bile acid concentration was <40 μmol/L [4]. In the study by Kawakita et al. [5] (2015), total bile acid (TBA) concentrations of 40–99.9 μmol/L and TBA ≥ 100 μmol/L were associated with an increased risk of meconium in the amniotic fluid (adjusted OR = 3.55 and OR = 4.55, respectively) [5].
The etiology of ICP is complex and not fully understood. The development of ICP is believed to be the result of many factors, such as genetic predisposition, hormonal factors, environmental factors and nutritional deficiencies, as well as the influence of chronic diseases on the predisposition to the development of cholestasis [6,7,8,9]. ICP causes abnormalities in laboratory test results of liver enzymes: aminotransferases: aspartate, alanine and γ-glutamyl transpeptidase (ASP, ALT and GGT) and increased values of bile acids (BAs). There are no universal consensus and guideline for the baseline of TBA for the diagnosis of ICP; however, the most common is serum level ≥ 10 μmol/L [10].
Bile acids are essential for the solubilization, digestion and absorption of dietary lipids and fat-soluble vitamins in the small intestine and are a signal molecule that regulates lipid, glucose and energy homeostasis. BAs regulate such many processes through activation of receptors including the farnesoid X receptor (FXR), the vitamin D receptor (VDR), the pregnane X receptor (PXR), membrane-bound G protein-coupled receptor Takeda G protein-coupled receptor 5 (TGR5), α5 β1 integrin, and sphingosine-1-phosphate receptor 2 (S1PR2). Several of these receptors are expressed outside of the gastrointestinal system, indicating that bile acids may have diverse functions throughout the body [11,12]. Bile acids are synthesized predominantly in the liver through the enzymatic oxidation of cholesterol via two different routes. The main pathway, which accounts for about 75% of BA production, is called the classical or neutral. This pathway is initiated by the rate-limiting enzyme, cholesterol 7alpha-monooxygenase (CYP7A1, EC:1.14.14.23), which catalyzes the hydroxylation of cholesterol to 7alpha-hydroxycholesterol. Cholesterol 7alpha-monooxygenase is encoded by the cytochrome P450 family 7 subfamily A member 1 gene (CYP7A1 Gene ID:1581) located on chromosome 8, regions q11–12, spans 10 kb and contains 6 exons and 5 introns [13]. Single nucleotide variant (SNV) in the CYP7A1 gene at the—204 location from the transcriptional start site (the—278 location from the translation initiation codon), conferring an A to C variation, may play a critical role in gene expression, leading to altered enzyme levels (rs3808607: the forward allele orientation G > T) [14,15]. This variant has been shown to influence serum levels of total cholesterol, LDL, and triglycerides [16,17].
The transcriptional regulation of the CYP7A1 gene is complex and involves numerous nuclear receptors (NRs). Farnesoid X receptor (FXRA, NR1H4, Gene ID: 9971, further on referred to as “FXR”) was the first NR identified as a bile acid receptor and was shown to regulate the transcription of key genes in bile acid metabolism, from synthesis and transport to detoxification [18,19]. The expression of the gene encoding FXR has been demonstrated in the adrenal glands, adipose tissue, endothelial wall, pancreas and kidneys. However, it is particularly high in the liver and intestine, which indicates an important role of this receptor in the regulation of enterohepatic circulation of BA [20]. A common FXR genetic variant rs56163822 (−1G > T), a SNV adjacent to the ATG start codon located within the Kozak consensus motif of the FXR gene, is linked to reduced transactivation of FXR gene targets [21]. Since the Kozak consensus motif ensures ribosomal binding to mRNA transcripts and efficient protein translation, genetic variation in this conserved sequence is associated with decreased protein translation [22,23].
FXR can regulate enterohepatic circulation by acting on BA transporters: apical sodium-dependent BA transporter (ASBT, SLC10A2), organic solute transporter-α and -β (OST-α, SLC51A; OST-β, SLC51B), Na+-taurocholate cotransporting polypeptide (NTCP, SLC10A1) and bile salt export pump (BSEP, ABCB11). FXR also regulates BA synthesis via two pathways, one in the liver by the small heterodimer partner 1 protein (SHP-1) and the other in the intestine involving fibroblast growth factor FGF15/19 (FGF15 in rodents; FGF19 in humans) [24]. As a transcription factor, FXR binds to DNA either as a monomer or as a heterodimer with a common partner for NRs, retinoid X receptor (RXRA, NR2B1 Gene ID: 6256), to regulate the expression of various genes involved in bile acid (BA), lipid, and glucose metabolisms [25,26]. Peroxisome proliferator-activated receptors (PPARs), a group of nuclear receptor proteins, also play an active role in the regulation of bile acid metabolism. Three types of PPARs have been identified: alpha, gamma, and delta (beta). Activation of PPARA induces CYP8B1 expression and inhibits CYP7A1 expression in the classical pathway; whereas in the alternative pathway, it inhibits CYP7B1 and CYP27A1 expression. The alpha isoform can also inhibit the FXR signaling pathway by competing with FXR for the RXRA receptor, can affect the FXR/SHP-1 pathway by inhibiting SHP-1 expression, and can increase the expression of bile acid transport proteins such as BSEP, MRP3, and MRP2 [24,27,28]. PPARA (NR1C1, Gene ID: 5465) is located on 22q13.3, and several single nucleotide polymorphisms described within this gene were associated with metabolic features like insulin resistance, dyslipidemia and cardiovascular risk factors. The rs1800206 variant is found in the fifth exon, which is a result of a transversion (C > G) in exon 5 that alters the amino acid sequence of the PPARA protein at the 162 codon (Leucine to Valine, L162V) [29,30]. The main relationships between proteins encoded by genes analyzed in the work are presented in Figure 1.
The goal of this study is to evaluate the association between polymorphic variants of the CYP7A1 gene, which is crucial for the synthesis of bile acids, and selected nuclear receptor genes (FXR, RXRA and PPARA) regulating its function in women with ICP.

2. Results

2.1. Characteristics of the Study Population

The present research included 96 ICP patients and 211 controls. General characteristics of study subjects are listed in Table 1, including age, body mass index (BMI), blood pressure, obstetric data of patients and selected clinical parameters of their newborns. Patients from both groups were of comparable age (30.43 ± 4.24 vs. 30.68 ± 4.67 in controls, p = 0.648), and there were no differences in blood pressure and BMI before pregnancy. More than half of women with ICP (56.26%) experienced preterm labor (<37 weeks) (p < 0.001). The median of pregnancy termination was two weeks lower in the ICP group compared to the controls (37 vs. 39 weeks, p < 0.001), which likely contributed to the observed smaller increase in BMI during pregnancy in this group (4.11 vs. 5.21 kg/m2, p < 0.001). Gestational weight gain (GWG) was calculated based on Institute of Medicine (IOM) guidelines [31] related to pre-pregnancy BMI: underweight, a gain of 12.5–18 kg; normal weight, a gain of 11.5–16 kg; overweight, a gain of 7–11.5 kg; and obese, a gain of 5–9 kg. In the cholestasis group, there were more women with insufficient body weight gain (41.67% vs. 24.64% in controls); normal and excessive body weight gain during pregnancy was more often observed in controls (p = 0.010). In women with cholestasis, pregnancies were more often terminated by surgical delivery (45.83% vs. 32.70% in controls, p = 0.037). We found a statistical difference between the case and the controls concerning the newborn weights (3091.03 ± 634.81 g vs. 3425.59 ± 433.82 g in controls, p < 0.001), whereas the mean for placental weight was lower in the ICP group (581.06 ± 150.63 g vs. 620.18 ± 111.37 g), but without statistical significance (p = 0.053). In patients with ICP, the median serum level of TBA was 19.75 [IQR: 14.93; 33.36] µmol/L. In most (79.17%), TBA values were below 40 µmol/L; in 17.71%, they were above; and in three women (3.12%), they reached values above 100 µmol/L. Pruritus was present in 93% of women, none of whom had jaundice.
In 72% of women, ICP symptoms appeared between 28 and 36 weeks of pregnancy, in 9%, in the second trimester of pregnancy (<28 weeks), and in 19%, after 37 weeks. The gestational time of onset of intrahepatic cholestasis symptoms in the study group is presented in Figure 2.

2.2. Genetic Association Analyses

We found no deviation from Hardy–Weinberg equilibrium (HWE) in controls regarding all studied SNVs (p > 0.05). The MAF (minor allele frequency) of rs3808607 in cases was significantly lower than controls (47.3% vs. 56.3%), which suggested the T allele of this CYP7A1 variant may be a protective factor against ICP risk (OR = 0.697, 95% CI: 0.495–0.981, p = 0.038) (Table 2).
The association between selected SNVs in ICP groups and controls was analyzed with logistic regression and presented in Table 3. Of the five genetic variants analyzed in this work, only rs3808607 CYP7A1 showed a statistically significant association with ICP. The GG genotype was more frequent in women with ICP compared to the control group (31.3% vs. 19.9%). Genotypes containing at least one T allele reduce the risk of ICP in the studied female population (GT: OR = 0.57, 95% CI: 0.32–1.04 and TT: OR = 0.51, 95% CI: 0.26–0.98, p = 0.093, AIC = 382.7). Under the dominant (OR = 0.55, 95% CI: 0.32–3.16, p = 0.032, AIC = 380.9) and log-additive (OR = 0.71, 95% CI: 0.51–1.00, p = 0.046, AIC = 381.4) models, the rs3808607 was significantly associated with a lower risk of ICP occurrence.

2.3. Serum TBA Level Stratified Analysis

Patients with ICP were divided into two groups based on TBA levels below (N = 76) and above 40 μmol/L (N = 20) according to guidelines of the Royal College of Obstetricians and Gynaecologists (RCOG). These guidelines classify ICP as mild (19–39 μmol/L), moderate ICP (40–99 μmol/L), and severe ICP (>100 μmol/L) [32].
Comparing the clinical data of the patients and their children, no statistically significant differences were observed between the groups. The genotype and allele frequencies rs3808607 (CYP7A1), rs56163822 (NR1H4), rs1800206 (PPARA), and rs749759 (NR2B1) were also not statistically significantly different. For rs11381416 RXRA gene, we found that the genotypes with A insertion are more frequent in women with TBA ≥ 40 μmol/L compared to the second subgroup (dominant model: 30.0% vs. 11.8% in group with TBA below 40 μmol/L, OR = 3.19, 95% CI: 0.98–10.41, p = 0.062, AIC = 98.8).

2.4. The Gestational Time of Onset of ICP Symptoms Stratified Analysis

We divided the study group into three subgroups based on the time of onset of ICP symptoms: before the third trimester (<28 weeks), early third trimester (28 to 36 weeks), and late third trimester (≥37 weeks). When analyzing the frequency of genotypes and alleles of the studied SNVs in such subgroups, no statistically significant differences were observed.
We observed statistically significant differences in the time of pregnancy termination (p < 0.001), newborn weight (p = 0.001) and placental weight (p = 0.012) between medians in at least two subgroups. Newborns of mothers who developed ICP symptoms before 28 weeks of pregnancy were born earlier—median 36 weeks [IQR: 32.00; 36.50]—with lower birth weights—median 2670 g [IQR: 1560; 2992.5]—and placentas—median 420 g [IQR: 286; 520] (Figure 3). Dunn’s test with Bonferroni correction for multiple comparisons found that the medians of gestational age at delivery differ significantly between all three subgroups (p < 0.001). For newborn weights, significant differences were between <28 weeks vs. ≥37 weeks group (p = 0.002) and between 28–36 weeks vs. ≥37 weeks (p = 0.026). The group with the earliest ICP symptoms differed statistically significantly from the other groups in terms of placental weight: 28–36 weeks (p = 0.019) and ≥37 weeks (p = 0.012) (Figure 3).
The differences in the results of BA, ALT and AST liver function tests between subgroups distinguished by the time of ICP symptoms occurrence are summarized in Table 4. The serum total bile acid levels increased with the time of onset of ICP symptoms, while serum aminotransferases were opposite. The results of the Kruskal-Wallis rank sum test showed no significant differences between the groups (ALT p = 0.145, AST p = 0.265, TBA p = 0.681).

2.5. The Relationship Between the SNVs and Liver Parameters

One of the main characteristics of ICP are elevated serum BA and transaminase levels. The Kruskal-Wallis test was conducted to examine the differences in these parameters according to the genotypes in women with ICP. It was observed that genotypes with A insertion of the NR2B1 rs11381416 variant are associated with an increase in the level of BA (p = 0.019), ASP (p = 0.079) and ALT (0.060) (Table 5). However, after Dunn’s test with Bonferroni correction was used, no significant differences were found between genotypes. Under the dominant model, significant differences were found for BA (medians for -/- was 18.21 μmol/L [IQR: 14.86; 25.10] vs. 34.30 μmol/L [IQR: 22.35; 58.85] for -/A and -/- genotypes, p = 0.008). Comparing the medians for these liver parameters between the (-) and A alleles, the differences were statistically significant. In women with A insertion, an increase in the levels of ALT (397.0 vs. 213.0 IU/L, p = 0.017), AST (186.0 vs. 114.4 IU/L, p = 0.032), and TBA (34.3 vs. 18.8 μmol/L, p = 0.002) was noted (Figure 4).

3. Discussion

In pregnancy, physiology changes dramatically; there are increases in plasma lipids, steroid hormones, binding globulins, and numerous metabolic changes to cope with fetal nutritional demands. In healthy pregnant women, total bile acids increase from the first trimester to late pregnancy [33,34,35]. In a study of white Portuguese women, the mean total bile acid concentration was 5.7 ± 0.4 μmol/L in nonpregnant women and slightly higher, although not significantly, in the group of pregnant women (6.6 ± 0.3 μmol/L, ranging from 1.7 μmol/L to 10.4 μmol/L). In contrast, in women with ICP, the mean concentration was 10 times higher and was 62.1 ± 8.2 μmol/L, ranging from 12.3 μmol/L to 219.4 μmol/L [36]. In our study, in healthy women, the median TBAs in serum collected the day after delivery was 1.10 μmol/L [IQR: 0.50; 2.10], and in women with cholestasis measured at diagnosis was 19.75 μmol/L [IQR: 14.93; 33.36]. In a similar study conducted on a population neighboring ours of healthy women from Germany (N = 38), serum bile acid postpartum examinations (conducted in the same way as in our case, 24 h after delivery) were 2.3 ± 1.2 µmol/L (in our case, the average was 1.71 ± 1.68 μmol/L), and in ICP (N = 98) patients in the third trimester, they were 39.0 ± 29.4 µmol/L (in our ICP women at diagnosis, mean ± SD was 29.84 ± 28.06 μmol/L) [37].
The prevalence of ICP has been reported to vary widely across populations and is more common in South Asia, South America, and Scandinavia [38]. Differences between populations are also noted by examining the levels of bile salts in serum. Black women had non-fasting TBA 25.8% higher (95% CI: 9.6–44.4%, p = 0.001) than white women, and 24.3% higher (95% CI: 5.7–46.1%, p = 0.008) than South Asian women. Levels from South Asian women were similar to those of white women (1.22% higher, 95% CI: 12.1 to 16.5%, p = 0.866) [39]. Sometimes even studies in the same population yield different results. For example, the study by Agarwal et al. [40] showed that pregnant Asian-Indian women have higher serum BA levels and therefore suggest that levels > 30 μmol/L can be considered as a cut-off point for diagnosing ICP in this geographical region [40]. In contrast, the study by Yadav et al. [41] reported that serum BA levels in healthy Indian non-pregnant and pregnant women are similar to those in other populations and can be used to diagnose ICP with an optimal cut-off being 8.6 μmol/L [41]. In a study of serum bile acid concentrations in European and South Asian women with or without GDM, Schoonejans et al. [42] found that serum BA homeostasis in late pregnancy was influenced by body mass index and GDM in an ethnicity-specific manner [42]. The incidence of ICP is reported to be 1% of all pregnancies in the European population, with a high occurrence in Sweden (1.5%). All our patients were of Caucasian race and from the Greater Poland Voivodship. Interestingly, in Poland, the estimated rate of ICP is 1.5%, but this is based on few studies on small populations [43,44,45].
Studies show that bile salt concentrations and the incidence of ICP depend on the season. A seasonal pattern for both fasting and postprandial total serum bile acid concentrations was observed in healthy pregnant women from Italy. The highest values measured in the winter season, declining during spring and summer, and with minimum values were measured in the autumn (p < 0.01 and 0.02, respectively) [46]. Studies from Scandinavia and Chile have shown evidence of seasonality in ICP, especially higher risks for colder months [47,48]. These results seem contradictory to Sanhal et al.’s [49] findings. In this study from Turkey, the number of new ICP cases was significantly lower in winter and higher in spring. The authors point out that the studies were conducted in lands belonging to different groups in the Köppen climate classification, which may influence the results [49]. The observed ethnic and seasonal differences in the incidence of ICP and in bile salt concentrations may be partly due to variability in diets. In the study by Trefflich et al. [50], fecal and serum bile acid concentrations were examined in 36 vegans and 36 omnivores. Serum primary and glycine-conjugated bile acids were higher in vegans than in omnivores (p ≤ 0.01). All fecal bile acids were significantly lower in vegans than in omnivores (p < 0.01). These results suggest that animal products and fat, in particular, may increase fecal bile acid levels and increase the risk of colorectal cancer [50]. It is also known that some plant compounds interact with bile acids during digestion in the small intestine. Furthermore, studies indicate the interactions of bile acids with the gut microbiota and their role in bile acid metabolism [51].
The etiology of ICP is complex, with some evidence pointing to genetic factors (familial clustering, increased risk of ICP in siblings of affected women, and increased incidence in certain ethnic groups, e.g., Chilean Araucanians) [52,53]. Most published studies of genetic variants associated with ICP etiopathogenesis have focused on the adenosine triphosphate-binding cassette (ABC) transporters family, mainly the ABCB4 gene coding for the multidrug resistance 3 (MDR3) protein and the ABCB11 that encodes bile salt export pump (BSEP) [53,54]. MDR3 translocates phosphatidylcholine across the hepatocanalicular membrane, whereas BSEP transports bile acids from the cytoplasm of the hepatocyte into the canaliculus. Polymorphisms were also studied in ABCC2 genes (coding multidrug resistance-associated protein 2—MRP2), and ATP8B1 (which encodes the familial intrahepatic cholestasis 1 protein—FIC1) in women with ICP [55,56,57].
Polymorphic variants of genes from the nuclear receptor family were also analyzed in ICP. Cases of genetic variation in the NR1I2 gene (encoding pregnane X receptor—PXR) have been reported in South American women [58]. The central role in bile acid homeostasis is played by the nuclear farnesoid receptor (FXR). Van Mill and coworkers [58] have analyzed sequencing data of 92 British ICP cases of mixed ethnicity and identified four heterozygous FXR variants. Two of them (rs61755050 and rs56163822) occur in Caucasians and were associated with reduced FXR activity, but only rs61755050 was significantly associated with a higher frequency of ICP (OR = 3.2; 95% CI: 1.1–11.2; p = 0.02). In the case of the rs56163822 variant, similarly to our results, no direct association with the etiology of ICP was demonstrated [59]. Upon bile acid activation, FXR binds heterodimerically with another nuclear receptor, retinoid X receptor. RXRA encoded by the NR2B1 gene participates in different metabolic pathways, but the influence of genetic variants in RXRA is poorly studied. In the study by Lima et al. (2013) [60], rs11381416 was genotyped in 622 healthy subjects from a Southern Brazilian community. Carriers of the A allele of the RXRA rs11381416 polymorphism have higher TG levels (1.80 ± 1.20 mmol/L) than those without an A insertion (1.52 ± 1.02 mmol/L; p = 0.020) [60]. In our ICP women with A insertion, we observed an increase in the levels of ALT (397.0 vs. 213.0 IU/L, p = 0.017), AST (186.0 vs. 114.4 IU/L, p = 0.032), and TBA (34.3 vs. 18.8 μmol/L, p = 0.002). We did not have detailed lipid profiles of women with ICP, which may show other associations between this RXRA gene variant and dyslipidemia in cholestatic patients. The relationship between ICP and abnormal lipid profiles was observed already in 1973 [61]. A meta-analysis of 786 participants by Zhan et al. (2022) revealed a significant association between ICP and maternal dyslipidemia, with elevated levels of triglycerides, total cholesterol, low-density lipoprotein cholesterol, and reduced high-density lipoprotein cholesterol levels vs. normal pregnancies [62].
The next nuclear receptor we studied was PPARA, which, like FXR, forms heterodimers with nuclear RXR after ligand binding. PPARA plays a central role in the regulation of multiple metabolic processes. When activated, it induces expression of genes involved in fatty acid uptake, reduction in triglyceride levels, and an increase in high-density lipoprotein expression [63,64,65]. Both nuclear receptors FXR and PPARA provide an intriguing, coordinated response to maintain energy balance in the liver depending on the nutritional status of the body. FXR is activated in the fed state by bile acids returning to the liver, while PPARA is activated in the fasted state in response to the free fatty acids produced by adipocyte lipolysis [24,66]. PPARA L162V polymorphism, associated with reduced gene activity, has important effects in dyslipidemia. The V162 minor allele is associated with an increase in triglycerides, total cholesterol, LDL, ApoB, ApoC3, the risk of type 2 diabetes, and a decrease in HDL [67,68]. In our study, no statistically significant association was observed between this PPARA gene variant and ICP risk.
Nuclear receptors modulate the activity of the key enzyme for bile acid synthesis, CYP7A1. Our results indicate an association between CYP7A1 rs3808607 and the risk of ICP, and an association of NR2B1 rs11381416 with higher liver function test values in women with pregnancy cholestasis. Additionally, individuals with the genotypes with the A duplication of the rs11381416 variant were 3.19 times more frequently observed in women with moderate to severe ICP (with TBA ≥ 40 μmol/L). To better understand the association between these variants and ICP, we searched available databases. In the National Center for Biotechnology Information (NCBI) ClinVar database [69], rs11381416 is not recorded, whereas rs3808607 is classified as “benign” based on two reports (VCV001229509.5, accessed 16 July 2025) [69]. It is also unclear whether and how these variants change the structure of proteins. The rs3808607 variant is located at the 5′ end of the gene, whereas rs11381416 is an intronic single-nucleotide duplication between exons 8 and 9. We could not find any studies on functional consequences (e.g., quantitative effects on gene expression, alternative splicing, functional effects on protein) based on experimental evidence for rs11381416. An interesting study in the case of CYP7A1 rs3808607 was conducted by Wang et al. [70]. They noted inconsistent research results regarding the rs3808607 variant. On the one hand, the G allele exhibits higher transcriptional activity than the T allele in reporter gene assays. However, association studies link the G allele to increased risk of atherosclerosis or greater lipid levels, which are predicted outcomes of reduced CYP7A1 activity. Furthermore, rs3808607 does not show a significant association with lipids in GWAS studies. Their study indicates the existence of two interacting variants, rs3808607 and rs9297994, which modulate CYP7A1 expression and are associated with the risk of coronary heart disease and diabetes. The functional rs9297994, frequently found in Caucasians and located in the downstream region of the CYP7A1 enhancer, is in strong linkage disequilibrium with the promoter SNP rs3808607 and exerts opposing effects on CYP7A1 mRNA expression. The minor G allele of rs3808607 is slightly more common than the minor G allele of rs9297994 in the European population (0.43 vs. 0.37), with a drastically different frequency in African Americans (rs3808607 MAF = 0.61, rs9297994 MAF = 0.035). This suggests that African Americans tend to have higher CYP7A1 activity than Europeans. In our study, the T allele of the rs3808607 variant was a protective factor against ICP risk (OR = 0.697, p = 0.038). The G allele, associated with higher CYP7A1 transcriptional activity and predicted higher BA concentrations, predominated in the ICP group. It is possible that more details regarding the association between CYP7A1 polymorphic variants and ICP could be obtained by analyzing the rs3808607 variant in combination with rs9297994.
ICP is associated with an increased risk of perinatal complications (premature birth, respiratory disorders, even stillbirth) [71]. We observed statistically significant differences between groups based on the time of onset of ICP symptoms for the mean values of the time of termination of pregnancy (p < 0.001), newborn weight (p < 0.001), and placental weight (p = 0.003). In the meta-analysis by Li et al. [72], the effect of ICP on neonatal weight was assessed, and a lower birth weight was found in neonates with ICP pregnancies compared with normal pregnancies. Moreover, similarly to our study group, early ICP was associated with lower birth weight than late ICP. Pooled data from two studies [73] indicated that the birth weight in the late-onset ICP group was heavier than in the early onset ICP group (WMD: 267 g, 95% CI: 168, 366) [72].

4. Materials and Methods

4.1. Study Population

A total of 311 subjects were enrolled in this hospital-based case-control study, comprising 96 ICP cases and 211 controls between 2018 and 2020. The study complied with ethical requirements and has been approved by the Ethics Committee of the Poznan University of Medical Sciences (No 842/13). Blood samples were obtained from the Department of Perinatology of Poznan University of Medical Sciences, Poznan.
Ninety-six women in a singleton pregnancy, of Caucasian race and Polish nationality, were qualified to the study group. ICP was recognized on the basis of the following clinical and laboratory criteria: itching (without rash) and/or an increase in TBA value in serum  ≥10 µmol/L on an empty stomach, increase in transaminases ALT and AST (>30 IU/L), and the resolution of symptoms within 2–3 weeks after delivery. Exclusion criteria of the study group contained existence of chronic liver diseases, viral hepatitis, autoimmune diseases, biliary obstruction, gestational hypertension or fetal anomalies. The controls consisted of pregnant women with no maternal diseases or fetal risks who had similar age and clinical characteristics.

4.2. Biochemical Analyses

Blood for testing was collected from pregnant women diagnosed with ICP before treatment with ursodeoxycholic acid (UDCA). The concentration of bile acids, total bilirubin, and aspartate and alanine aminotransferases was determined in the blood serum of women with ICP. In a group of healthy pregnant women, bile acid concentrations were determined after delivery. Roche Cobas test BILT3 (Cat. No. 08056960190, Roche Diagnostics, Mannheim, Germany) was used to quantify total bilirubin. Serum ALT and AST were measured with pyridoxal phosphate activation as suggested by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC II) using Roche tests ALTP2 (Cat. No. 08104697190, Roche Diagnostics, Mannheim, Germany) and ASTP2 (Cat. No. 08104719190, Roche Diagnostics, Mannheim, Germany). The total volume of bile acids in serum was determined using the 5th Generation Enzymatic Colorimetric RX Series kit (Cat. No. BI3863, Randox Laboratories Ltd., Crumlin, UK). The measurements were conducted on a Cobas Pro analyzer (Roche Diagnostics, Basel, Switzerland). All tests were carried out at the Central Laboratory Gynecology and Obstetrics Clinical Hospital, University of Medical Sciences, Poznan, Poland, a certified facility meeting the criteria of ISO 9001:2015-10 (certificate number J-779/13/2023) [74].

4.3. DNA Extraction

2 mL ethylenediaminetetraacetic acid anticoagulated peripheral blood samples were collected from all subjects. Genomic DNA was extracted by the QIAamp DNA Blood Mini Kit (Cat. No.: 69506, Qiagen, Hilden, Germany). Nanodrop 2000 Spectrophotometer (Thermo Scientific, Waltham, MA USA) was used to evaluate the concentration (A260) and purity (A260/A280 absorbance ratio) for each DNA sample.

4.4. Selection of the SNVs

Figure 5 shows the network of connections between the genes we analyzed and their closest neighboring proteins drawn by the STRING database version 12.0 accessed on 2 October 2024 [75].
In this study, five polymorphic variants in four genes regulating bile acid biosynthesis were selected: rs3808607 (CYP7A1), rs56163822 (NR1H4), rs1800206 (PPARA), rs749759, and rs11381416 (RXRA). Basic information about the analyzed SNVs and allele frequency distributions in European populations from the 1000Genomes Project is presented in Table 6.
Genotyping was performed by polymerase chain reaction/restriction fragment length polymorphism (PCR/RFLP) using methods described in the previous literature [76,77,78,79,80]. The primers and restriction enzymes used for the RFLP reactions are presented in Table 7. DNA amplification was performed in a 15 μL volume containing 50 ng genomic DNA, 0.25 μM of each primer, 1 U of Taq DNA polymerase and respective buffer (DreamTaq Green DNA polymerase, Cat. No.: EP0712, Thermo Fisher Scientific, Waltham, MA, USA), and 200 μM of each deoxynucleotide (Cat. No. R0241, Thermo Fisher Scientific, Waltham, MA, USA). Samples were denatured in a thermocycler (DNA Engine Dyad® Thermal Cycler, Bio-Rad Laboratories, Inc., Hercules, CA, USA). The variants were detected by restriction analysis using Thermo Fisher Scientific (Waltham, MA, USA) enzymes: BseGI (Cat. No. ER0871), Eco31I (Cat. No. ER0291), BstXI (Cat. No. ER1021), EcoO109I (Cat. No. ER0261), BglI (Cat. No. ER0071). Products were analyzed by electrophoresis on agarose gel with Midori Green Advanced DNA Stain (Cat. No. MG04, Nippon Genetics, Düren, Germany). Positive and negative controls were used in the reactions. 10% of genotype determinations were repeated in independent experiments with complete agreement.

4.5. Statistical Analysis

All statistical analyses were conducted in the R programming environment (version 4.3.1, The R Foundation for Statistical Computing, https://cran.r-project.org accessed on 25 November 2024) [81]. For continuous variables, the Shapiro-Wilk test was used to verify normality. Normally distributed variables were expressed as mean ± standard deviation (SD), and in the absence of normal distribution as median and interquartile range (IQR). Nominal variables are presented as observation counts and percentage. The chi-square test or Fisher’s exact test was used for nominal scales, and the t-test or Mann-Whitney U test for ordinal scales. Comparisons between a larger number of groups were made using the Kruskal–Wallis test with the post hoc Dunn–Bonferroni comparison procedure. Genotype and allele frequency distributions, in addition to HWE probabilities, were determined applying different models of inheritance (codominant, dominant, recessive, over-dominant, and log-additive) using the SNPassoc package version 2.1-0 [82]; p < 0.05 were considered statistically significant.

5. Conclusions

In conclusion, normal pregnancy is characterized by metabolic changes that lead to elevated serum bile acid levels and dyslipidemia. Nuclear receptors, due to their ability to translate nutritional signals into gene expression, play an important role in regulating metabolic pathways that influence changes in these parameters. Disruptions in nuclear receptor signaling caused by polymorphic variants in the genes encoding them can result in pregnancy disorders such as ICP. Although the importance of nuclear receptors in bile acid metabolism is crucial, the influence of genetic variants on ICP is poorly studied. Our study suggests that polymorphisms in CYP7A1 and RXRA (NR2B1) genes may affect bile acid metabolism and ICP. However, there are several limitations to consider in our study. First, we analyzed only five SNVs of genes related to bile acid metabolism. Moreover, the obtained data were based on a small number of samples, and thus the results of this work must be interpreted cautiously. Future studies should also take into account the influence of environmental factors, especially the diet of the patients. A more complete understanding of the nutrients’ regulatory effects on metabolism via nuclear receptors may provide new insights into the pathophysiology and treatment of ICP.

Author Contributions

Conceptualization, K.P.; methodology, K.P. and G.K.; software and visualization, T.M.K. and W.M.; validation, M.O. and A.S.-M.; formal analysis, A.S.-M. and G.K.; investigation, A.K. and M.B.; resources, P.J.O., G.K. and K.P.; material collection, K.P. and T.M.K.; data curation, K.P. and G.K.; writing—original draft preparation, M.O., A.K. and P.J.O.; writing—review and editing, A.S.-M. and W.M.; supervision, M.B. and M.O.; project administration, A.S.-M. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of the Poznan University of Medical Sciences (No 842/13, 10 October 2013).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Malarkiewicz, P.; Nowacka, U.; Januszaniec, A.; Mankiewicz, A.; Kozłowski, S.; Issat, T. Intrahepatic Cholestasis of Pregnancy during COVID-19 Pandemic. Medicina 2024, 60, 676. [Google Scholar] [CrossRef] [PubMed]
  2. Lee, R.H.; Greenberg, M.; Metz, T.D.; Pettker, C.M. Society for Maternal-Fetal Medicine Consult Series #53: Intrahepatic cholestasis of pregnancy: Replaces Consult #13, April 2011. Am. J. Obstet. Gynecol. 2021, 224, B2–B9. [Google Scholar] [CrossRef] [PubMed]
  3. Floreani, A.; Caroli, D.; Lazzari, R.; Memmo, A.; Vidali, E.; Colavito, D.; D’Arrigo, A.; Leon, A.; Romero, R.; Gervasi, M.T. Intrahepatic cholestasis of pregnancy: New insights into its pathogenesis. J. Matern.-Fetal Neonatal Med. 2013, 26, 1410–1415. [Google Scholar] [CrossRef] [PubMed]
  4. Glantz, A.; Marschall, H.U.; Mattsson, L.A. Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. Hepatology 2004, 40, 467–474. [Google Scholar] [CrossRef]
  5. Kawakita, T.; Parikh, L.I.; Ramsey, P.S.; Huang, C.C.; Zeymo, A.; Fernandez, M.; Smith, S.; Iqbal, S.N. Predictors of adverse neonatal outcomes in intrahepatic cholestasis of pregnancy. Am. J. Obstet. Gynecol. 2015, 213, 570.e1–570.e8. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  6. Majsterek, M.; Wierzchowska-Opoka, M.; Makosz, I.; Kreczyńska, L.; Kimber-Trojnar, Ż.; Leszczyńska-Gorzelak, B. Bile Acids in Intrahepatic Cholestasis of Pregnancy. Diagnostics 2022, 12, 2746. [Google Scholar] [CrossRef] [PubMed]
  7. Pillarisetty, L.S.; Sharma, A. Pregnancy Intrahepatic Cholestasis. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, 2024. [Google Scholar]
  8. Waheed, A.M.I.; Jaiswal, A.; Yelne, S.; Nandanwar, V. Navigating Perinatal Challenges: A Comprehensive Review of Cholestasis of Pregnancy and Its Impact on Maternal and Fetal Health. Cureus 2024, 16, e58699. [Google Scholar] [CrossRef]
  9. Zhuo, H.; Fan, J.; Yao, L.; Zheng, L.; Chai, Y. MDR3 rs2109505 and rs1202283 polymorphisms are associated with susceptibility to intrahepatic cholestasis of pregnancy: A meta-analysis. Adv. Clin. Exp. Med. 2023, 32, 1347–1356. [Google Scholar] [CrossRef]
  10. Obiegbusi, C.N.; Dong, X.J.; Obiegbusi, S.C.; Jin, X.; Okoene, I.K. Predictors of Adverse Fetal Outcomes in Intrahepatic Cholestasis of Pregnancy (ICP): A Narrative Review. Reprod. Sci. 2024, 31, 341–351. [Google Scholar] [CrossRef]
  11. Copple, B.L.; Li, T. Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules. Pharmacol. Res. 2016, 104, 9–21. [Google Scholar] [CrossRef]
  12. Perino, A.; Schoonjans, K. Metabolic Messengers: Bile acids. Nat. Metab. 2022, 4, 416–423. [Google Scholar] [CrossRef] [PubMed]
  13. Cohen, J.C.; Cali, J.J.; Jelinek, D.F.; Mehrabian, M.; Sparkes, R.S.; Lusis, A.J.; Russell, D.W.; Hobbs, H.H. Cloning of the human cholesterol 7 alpha-hydroxylase gene (CYP7) and localization to chromosome 8q11–q12. Genomics 1992, 14, 153–161. [Google Scholar] [CrossRef]
  14. De Castro-Orós, I.; Pampín, S.; Cofán, M.; Mozas, P.; Pintó, X.; Salas-Salvadó, J.; Rodríguez-Rey, J.C.; Ros, E.; Civeira, F.; Pocoví, M. Promoter variant −204A > C of the cholesterol 7α-hydroxylase gene: Association with response to plant sterols in humans and increased transcriptional activity in transfected HepG2 cells. Clin. Nutr. 2011, 30, 239–246. [Google Scholar] [CrossRef]
  15. Sezer, E.; Demirdöğen, C.B.; Demirkaya, Ş.; Bulut, G.; Akkulak, M.; Evin, E.; Adalı, O. Association of cholesterol 7α-hydroxylase (CYP7A1) promoter polymorphism (rs3808607) and cholesterol 24S-hydroxylase (CYP46A1) intron 2 polymorphism (rs754203) with serum lipids, vitamin D levels, and multiple sclerosis risk in the Turkish population. Neurol. Sci. 2022, 43, 2611–2620. [Google Scholar] [CrossRef]
  16. Lu, Y.; Feskens, E.J.; Boer, J.M.; Müller, M. The potential influence of genetic variants in genes along bile acid and bile metabolic pathway on blood cholesterol levels in the population. Atherosclerosis 2010, 210, 14–27. [Google Scholar] [CrossRef]
  17. Couture, P.; Otvos, J.D.; Cupples, L.A.; Wilson, P.W.; Schaefer, E.J.; Ordovas, J.M. Association of the A-204C polymorphism in the cholesterol 7alpha-hydroxylase gene with variations in plasma low density lipoprotein cholesterol levels in the Framingham Offspring Study. J. Lipid. Res. 1999, 40, 1883–1889. [Google Scholar] [CrossRef]
  18. Makishima, M.; Okamoto, A.Y.; Repa, J.J.; Tu, H.; Learned, R.M.; Luk, A.; Hull, M.V.; Lustig, K.D.; Mangelsdorf, D.J.; Shan, B. Identification of a nuclear receptor for bile acids. Science 1999, 284, 1362–1365. [Google Scholar] [CrossRef] [PubMed]
  19. Li, T.; Chiang, J.Y. Nuclear receptors in bile acid metabolism. Drug Metab. Rev. 2013, 45, 145–155. [Google Scholar] [CrossRef] [PubMed]
  20. Stojancevic, M.; Stankov, K.; Mikov, M. The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease. Can. J. Gastroenterol. 2012, 26, 31–37. [Google Scholar] [CrossRef]
  21. Marzolini, C.; Tirona, R.G.; Gervasini, G.; Poonkuzhali, B.; Assem, M.; Lee, W.; Leake, B.F.; Schuetz, J.D.; Schuetz, E.G.; Kim, R.B. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol. Endocrinol. 2007, 21, 1769–1780. [Google Scholar] [CrossRef]
  22. Acevedo, J.M.; Hoermann, B.; Schlimbach, T.; Teleman, A.A. Changes in global translation elongation or initiation rates shape the proteome via the Kozak sequence. Sci. Rep. 2018, 8, 4018. [Google Scholar] [CrossRef] [PubMed]
  23. Wilson, A.; Wang, Q.; Almousa, A.A.; Jansen, L.E.; Choi, Y.H.; Schwarz, U.I.; Kim, R.B. Genetic variation in the farnesoid X-receptor predicts Crohn’s disease severity in female patients. Sci. Rep. 2020, 10, 11725. [Google Scholar] [CrossRef]
  24. Zhou, S.; You, H.; Qiu, S.; Yu, D.; Bai, Y.; He, J.; Cao, H.; Che, Q.; Guo, J.; Su, Z. A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR). Biomed. Pharmacother. 2022, 154, 113577. [Google Scholar] [CrossRef] [PubMed]
  25. Wang, N.; Zou, Q.; Xu, J.; Zhang, J.; Liu, J. Ligand binding and heterodimerization with retinoid X receptor α (RXRα) induce farnesoid X receptor (FXR) conformational changes affecting coactivator binding. J. Biol. Chem. 2018, 293, 18180–18191. [Google Scholar] [CrossRef]
  26. Wang, Y.D.; Chen, W.D.; Moore, D.D.; Huang, W. FXR: A metabolic regulator and cell protector. Cell Res. 2008, 18, 1087–1095. [Google Scholar] [CrossRef] [PubMed]
  27. Christofides, A.; Konstantinidou, E.; Jani, C.; Boussiotis, V.A. The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. Metabolism 2021, 114, 154338. [Google Scholar] [CrossRef]
  28. Sun, Y.; Zhang, L.; Jiang, Z. The role of peroxisome proliferator-activated receptors in the regulation of bile acid metabolism. Basic Clin. Pharmacol. Toxicol. 2024, 134, 315–324. [Google Scholar] [CrossRef]
  29. Yong, E.L.; Li, J.; Liu, M.H. Single gene contributions: Genetic variants of peroxisome proliferator-activated receptor (isoforms alpha, beta/delta and gamma) and mechanisms of dyslipidemias. Curr. Opin. Lipidol. 2008, 19, 106–112. [Google Scholar] [CrossRef]
  30. Mazzotti, D.R.; Singulane, C.C.; Ota, V.K.; Rodrigues, T.P.; Furuya, T.K.; de Souza, F.J.; Cordeiro, B.G.; Magalhães, C.; Chen, E.S.; Jacomini, A.; et al. PPARα polymorphisms as risk factors for dyslipidemia in a Brazilian population. Mol. Genet. Metab. 2011, 102, 189–193. [Google Scholar] [CrossRef]
  31. Institute of Medicine (US) and National Research Council (US), Committee to Reexamine IOM Pregnancy Weight Guidelines. Weight Gain During Pregnancy: Reexamining the Guidelines; Rasmussen, K.M., Yaktine, A.L., Eds.; National Academies Press (US): Washington, DC, USA, 2009. [Google Scholar] [PubMed]
  32. Girling, J.; Knight, C.L.; Chappell, L. Royal College of Obstetricians and Gynaecologists. Intrahepatic cholestasis of pregnancy: Green-top Guideline No. 43 June 2022. BJOG 2022, 129, e95–e114. [Google Scholar] [CrossRef]
  33. Soma-Pillay, P.; Nelson-Piercy, C.; Tolppanen, H.; Mebazaa, A. Physiological changes in pregnancy. Cardiovasc. J. Afr. 2016, 27, 89–94. [Google Scholar] [CrossRef]
  34. Gagnon, M.; Trottier, J.; Weisnagel, S.J.; Gagnon, C.; Carreau, A.M.; Barbier, O.; Morisset, A.S. Bile acids during pregnancy: Trimester variations and associations with glucose homeostasis. Health Sci. Rep. 2021, 4, e243. [Google Scholar] [CrossRef]
  35. Zhu, B.; Yin, P.; Ma, Z.; Ma, Y.; Zhang, H.; Kong, H.; Zhu, Y. Characteristics of bile acids metabolism profile in the second and third trimesters of normal pregnancy. Metabolism 2019, 95, 77–83. [Google Scholar] [CrossRef]
  36. Brites, D.; Rodrigues, C.M.; van-Zeller, H.; Brito, A.; Silva, R. Relevance of serum bile acid profile in the diagnosis of intrahepatic cholestasis of pregnancy in an high incidence area: Portugal. Eur. J. Obstet. Gynecol. Reprod. Biol. 1998, 80, 31–38. [Google Scholar] [CrossRef] [PubMed]
  37. Nees, J.; Ammon, F.J.; Mueller, J.; Fluhr, H.; Mueller, S. Liver stiffness in pregnant women with intrahepatic cholestasis of pregnancy: A case control study. World J. Hepatol. 2023, 15, 904–913. [Google Scholar] [CrossRef]
  38. Gao, X.X.; Ye, M.Y.; Liu, Y.; Li, J.Y.; Li, L.; Chen, W.; Lu, X.; Nie, G.; Chen, Y.H. Prevalence and risk factors of intrahepatic cholestasis of pregnancy in a Chinese population. Sci. Rep. 2020, 10, 16307. [Google Scholar] [CrossRef] [PubMed]
  39. Mitchell, A.L.; Ovadia, C.; Syngelaki, A.; Souretis, K.; Martineau, M.; Girling, J.; Vasavan, T.; Fan, H.M.; Seed, P.T.; Chambers, J.; et al. Re-evaluating diagnostic thresholds for intrahepatic cholestasis of pregnancy: Case-control and cohort study. BJOG 2021, 128, 1635–1644. [Google Scholar] [CrossRef]
  40. Agarwal, N.; Mahey, R.; Kulshrestha, V.; Kriplani, A.; Saraya, A.; Sachdev, V. Serum Bile Acids in Intrahepatic Cholestasis of Pregnancy (ICP), Versus Pregnant and Nonpregnant Controls in Asian Indian Women and a Proposed Scoring to Optimize Management in ICP. J. Obstet. Gynaecol. India 2022, 72, 218–224. [Google Scholar] [CrossRef] [PubMed]
  41. Yadav, S.; Goel, A.; Lingaiah, R.; Pradhan, M.; Katiyar, H.; Aggarwal, R. Serum Bile Acid Levels in Women With Intrahepatic Cholestasis of Pregnancy in India. J. Clin. Exp. Hepatol. 2022, 12, 379–383. [Google Scholar] [CrossRef]
  42. Schoonejans, J.M.; Fan, H.M.; Mitchell, A.L.; Lövgren-Sandblom, A.; Sukumar, N.; Periyathambi, N.; Weldeselassie, Y.; Seed, P.T.; Molinaro, A.; Marschall, H.U.; et al. Serum bile acid measurements in women of European and South Asian ethnicity with or without gestational diabetes mellitus: A cohort study. BJOG 2024, 131, 1218–1228. [Google Scholar] [CrossRef]
  43. Geenes, V.; Williamson, C. Intrahepatic cholestasis of pregnancy. World J. Gastroenterol. 2009, 15, 2049–2066. [Google Scholar] [CrossRef]
  44. Wójcicka-Jagodzińska, J.; Kuczyńska-Sicińska, J.; Czajkowski, K.; Smolarczyk, R. Carbohydrate metabolism in the course of intrahepatic cholestasis in pregnancy. Am. J. Obstet. Gynecol. 1989, 161, 959–964. [Google Scholar] [CrossRef] [PubMed]
  45. Majewska, A.; Godek, B.; Bomba-Opon, D.; Wielgos, M. Association between intrahepatic cholestasis in pregnancy and gestational diabetes mellitus. A retrospective analysis. Ginekol. Pol. 2019, 90, 458–463. [Google Scholar] [CrossRef] [PubMed]
  46. Huri, M.; Seravalli, V.; Lippi, C.; Tofani, L.; Galli, A.; Petraglia, F.; Di Tommaso, M. Intrahepatic cholestasis of pregnancy—Time to redefine the reference range of total serum bile acids: A cross-sectional study. BJOG 2022, 129, 1887–1896. [Google Scholar] [CrossRef]
  47. Berg, B.; Helm, G.; Petersohn, L.; Tryding, N. Cholestasis of pregnancy: Clinical and laboratory studies. Acta Obstet. Gynecol. Scand. 1986, 65, 107–113. [Google Scholar] [CrossRef] [PubMed]
  48. Reyes, H.; Gonzalez, M.C.; Ribalta, J.; Aburto, H.; Matus, C.; Schramm, G.; Katz, R.; Medina, E. Prevalence of intrahepatic cholestasis of pregnancy in Chile. Ann. Intern. Med. 1978, 88, 487–493. [Google Scholar] [CrossRef]
  49. Sanhal, C.Y.; Dağlar, K.; Kara, Ö.; Kırbaş, A.; Uygur, D.; Yücel, A. Seasonal Impact in the Frequency of Intrahepatic Cholestasis of Pregnancy. Gynecol. Obstet Reprod. Med. 2016, 22, 5–9. [Google Scholar] [CrossRef]
  50. Trefflich, I.; Marschall, H.U.; Giuseppe, R.D.; Ståhlman, M.; Michalsen, A.; Lampen, A.; Abraham, K.; Weikert, C. Associations between Dietary Patterns and Bile Acids-Results from a Cross-Sectional Study in Vegans and Omnivores. Nutrients 2019, 12, 47. [Google Scholar] [CrossRef]
  51. Naumann, S.; Haller, D.; Eisner, P.; Schweiggert-Weisz, U. Mechanisms of Interactions between Bile Acids and Plant Compounds-A Review. Int. J. Mol. Sci. 2020, 21, 6495. [Google Scholar] [CrossRef]
  52. Dixon, P.H.; Williamson, C. The molecular genetics of intrahepatic cholestasis of pregnancy. Obstet. Med. 2008, 1, 65–71. [Google Scholar] [CrossRef]
  53. Abu-Hayyeh, S.; Papacleovoulou, G.; Williamson, C. Nuclear receptors, bile acids and cholesterol homeostasis series—Bile acids and pregnancy. Mol. Cell. Endocrinol. 2013, 368, 120–128. [Google Scholar] [CrossRef] [PubMed]
  54. Zöllner, J.; Williamson, C.; Dixon, P.H. Genetic issues in ICP. Obstet. Med. 2024, 17, 157–161. [Google Scholar] [CrossRef]
  55. Sookoian, S.; Castaño, G.; Burgueño, A.; Gianotti, T.F.; Pirola, C.J. Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J. Hepatol. 2008, 48, 125–132. [Google Scholar] [CrossRef]
  56. Müllenbach, R.; Bennett, A.; Tetlow, N.; Patel, N.; Hamilton, G.; Cheng, F.; Chambers, J.; Howard, R.; Taylor-Robinson, S.D.; Williamson, C. ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy. Gut 2005, 54, 829–834. [Google Scholar] [CrossRef]
  57. Painter, J.N.; Savander, M.; Ropponen, A.; Nupponen, N.; Riikonen, S.; Ylikorkala, O.; Lehesjoki, A.E.; Aittomäki, K. Sequence variation in the ATP8B1 gene and intrahepatic cholestasis of pregnancy. Eur. J. Hum. Genet. 2005, 13, 435–439. [Google Scholar] [CrossRef]
  58. Castaño, G.; Burgueño, A.; Fernández Gianotti, T.; Pirola, C.J.; Sookoian, S. The influence of common gene variants of the xenobiotic receptor (PXR) in genetic susceptibility to intrahepatic cholestasis of pregnancy. Aliment. Pharmacol. Ther. 2010, 31, 583–592. [Google Scholar] [CrossRef] [PubMed]
  59. Van Mil, S.W.; Milona, A.; Dixon, P.H.; Mullenbach, R.; Geenes, V.L.; Chambers, J.; Shevchuk, V.; Moore, G.E.; Lammert, F.; Glantz, A.G.; et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 2007, 133, 507–516. [Google Scholar] [CrossRef]
  60. Lima, L.O.; Almeida, S.; Hutz, M.H.; Fiegenbaum, M. PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms and lipid and lipoprotein levels in a Southern Brazilian population. Mol. Biol. Rep. 2013, 40, 1241–1247. [Google Scholar] [CrossRef]
  61. Johnson, P. Studies in cholestasis of pregnancy with special reference to lipids and lipoproteins. Acta Obstet. Gynecol. Scand. Suppl. 1973, 27, 1–80. [Google Scholar] [PubMed]
  62. Zhan, Y.; Xu, T.; Chen, T.; Wang, X. Intrahepatic cholestasis of pregnancy and maternal dyslipidemia: A systematic review and meta-analysis. Acta Obstet. Gynecol. Scand. 2022, 101, 719–727. [Google Scholar] [CrossRef]
  63. Jaffe, S.; Normand, N.; Jayaram, A.; Orfanelli, T.; Doulaveris, G.; Passos, M.; Kanninen, T.T.; Bongiovanni, A.M.; Linhares, I.M.; Witkin, S.S. Unique variation in genetic selection among Black North American women and its potential influence on pregnancy outcome. Med. Hypotheses 2013, 81, 919–922. [Google Scholar] [CrossRef]
  64. Fruchart, J.C. Peroxisome proliferator-activated receptor-alpha (PPARalpha): At the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009, 205, 1–8. [Google Scholar] [CrossRef]
  65. Changizi, Z.; Kajbaf, F.; Moslehi, A. An Overview of the Role of Peroxisome Proliferator-activated Receptors in Liver Diseases. J. Clin. Transl. Hepatol. 2023, 11, 1542–1552. [Google Scholar] [CrossRef] [PubMed]
  66. Kim, K.H.; Moore, D.D. Regulation of Liver Energy Balance by the Nuclear Receptors Farnesoid X Receptor and Peroxisome Proliferator Activated Receptor α. Dig. Dis. 2017, 35, 203–209. [Google Scholar] [CrossRef] [PubMed]
  67. Contreras, A.V.; Torres, N.; Tovar, A.R. PPAR-α as a key nutritional and environmental sensor for metabolic adaptation. Adv. Nutr. 2013, 4, 439–452. [Google Scholar] [CrossRef] [PubMed]
  68. Ruscica, M.; Busnelli, M.; Runfola, E.; Corsini, A.; Sirtori, C.R. Impact of PPAR-Alpha Polymorphisms-The Case of Metabolic Disorders and Atherosclerosis. Int. J. Mol. Sci. 2019, 20, 4378. [Google Scholar] [CrossRef]
  69. National Center for Biotechnology Information. ClinVar; [VCV001229509.5]. Available online: https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV001229509.5 (accessed on 16 July 2025).
  70. Wang, D.; Hartmann, K.; Seweryn, M.; Sadee, W. Interactions Between Regulatory Variants in CYP7A1 (Cholesterol 7α-Hydroxylase) Promoter and Enhancer Regions Regulate CYP7A1 Expression. Circ. Genom. Precis. Med. 2018, 11, e002082. [Google Scholar] [CrossRef]
  71. Piechota, J.; Jelski, W. Intrahepatic Cholestasis in Pregnancy: Review of the Literature. J. Clin. Med. 2020, 9, 1361. [Google Scholar] [CrossRef]
  72. Li, L.; Chen, Y.H.; Yang, Y.Y.; Cong, L. Effect of Intrahepatic Cholestasis of Pregnancy on Neonatal Birth Weight: A Meta-Analysis. J. Clin. Res. Pediatr. Endocrinol. 2018, 10, 38–43. [Google Scholar] [CrossRef]
  73. Zhou, L.; Qi, H.B.; Luo, X. Analysis of clinical characteristics and perinatal outcome of early-onset intrahepatic cholestasis of pregnancy. Zhonghua Fu Chan Ke Za Zhi 2013, 48, 20–24. [Google Scholar]
  74. ISO Standard No. 9001:2015; Quality Management Systems—Requirements, 5th ed. International Organization for Standardization: Geneva, Switzerland, 2015.
  75. Szklarczyk, D.; Kirsch, R.; Koutrouli, M.; Nastou, K.; Mehryary, F.; Hachilif, R.; Gable, A.L.; Fang, T.; Doncheva, N.T.; Pyysalo, S.; et al. The STRING database in 2023: Protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023, 51, D638–D646. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  76. Hagiwara, T.; Kono, S.; Yin, G.; Toyomura, K.; Nagano, J.; Mizoue, T.; Mibu, R.; Tanaka, M.; Kakeji, Y.; Maehara, Y.; et al. Genetic polymorphism in cytochrome P450 7A1 and risk of colorectal cancer: The Fukuoka Colorectal Cancer Study. Cancer Res. 2005, 65, 2979–2982. [Google Scholar] [CrossRef] [PubMed]
  77. Iwata, R.; Baur, K.; Stieger, B.; Mertens, J.C.; Daly, A.K.; Frei, P.; Braun, J.; Vergopoulos, A.; Stickel, F.; Sabrane, K.; et al. A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. Clin. Sci. 2011, 120, 287–296. [Google Scholar] [CrossRef] [PubMed]
  78. Grzegorzewska, A.E.; Świderska, M.K.; Mostowska, A.; Warchoł, W.; Jagodziński, P.P. Polymorphisms of Vitamin D Signaling Pathway Genes and Calcium-Sensing Receptor Gene in respect to Survival of Hemodialysis Patients: A Prospective Observational Study. Int. J. Endocrinol. 2016, 2016, 2383216. [Google Scholar] [CrossRef]
  79. Vasků, V.; Bienertová Vasků, J.; Pávková Goldbergová, M.; Vasků, A. Three retinoid X receptor gene polymorphisms in plaque psoriasis and psoriasis guttata. Dermatology 2007, 214, 118–124. [Google Scholar] [CrossRef]
  80. Lacquemant, C.; Lepretre, F.; Pineda Torra, I.; Manraj, M.; Charpentier, G.; Ruiz, J.; Staels, B.; Froguel, P. Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab. 2000, 26, 393–401. [Google Scholar]
  81. R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2023; Available online: https://www.R-project.org/ (accessed on 25 November 2024).
  82. Moreno, V.; Gonzalez, J.; Pelegri, D. SNPassoc: SNPs-Based Whole Genome Association Studies. R Package Version 2.1-0. 2022. Available online: https://CRAN.R-project.org/package=SNPassoc (accessed on 25 November 2024).
Ijms 26 07456 g001
Figure 1. The main relationships between proteins encoded by genes analyzed in the work. Bile acids (BA) are produced in the liver from cholesterol by CYP7A1 and secreted into the gallbladder. From the ileum, they are reabsorbed in enterocytes, where they activate FXR, which stimulates transcription of the FGF19 gene. The FGF19 protein is secreted into the portal circulation and in the liver binds itself to the receptor FGFR4 to reduce CYP7A1 expression. Bile acids synthesis in the liver is also regulated by FXR, which transcriptionally increases SHP protein expression, which reduces CYP7A1 expression. PPARA competes with FXR for the RXRA receptor and may downregulate SHP expression. Abbreviations: BA, bile acids; FA, fatty acids; CYP7A1, cholesterol 7alpha-monooxygenase; FGF, fibroblast growth factor; FGFR4, fibroblast growth factor receptor 4; FXRA, farnesoid X receptor alpha; NTCP, Na+-taurocholate cotransporting polypeptide; PPARA, peroxisome proliferator-activated receptor alpha; RXRA, retinoid X receptor alpha; SHP, small heterodimer partner; 9cRA, 9-cis retinoic acid.
Figure 1. The main relationships between proteins encoded by genes analyzed in the work. Bile acids (BA) are produced in the liver from cholesterol by CYP7A1 and secreted into the gallbladder. From the ileum, they are reabsorbed in enterocytes, where they activate FXR, which stimulates transcription of the FGF19 gene. The FGF19 protein is secreted into the portal circulation and in the liver binds itself to the receptor FGFR4 to reduce CYP7A1 expression. Bile acids synthesis in the liver is also regulated by FXR, which transcriptionally increases SHP protein expression, which reduces CYP7A1 expression. PPARA competes with FXR for the RXRA receptor and may downregulate SHP expression. Abbreviations: BA, bile acids; FA, fatty acids; CYP7A1, cholesterol 7alpha-monooxygenase; FGF, fibroblast growth factor; FGFR4, fibroblast growth factor receptor 4; FXRA, farnesoid X receptor alpha; NTCP, Na+-taurocholate cotransporting polypeptide; PPARA, peroxisome proliferator-activated receptor alpha; RXRA, retinoid X receptor alpha; SHP, small heterodimer partner; 9cRA, 9-cis retinoic acid.
Ijms 26 07456 g001
Ijms 26 07456 g002
Figure 2. The gestational time of onset of intrahepatic cholestasis symptoms.
Figure 2. The gestational time of onset of intrahepatic cholestasis symptoms.
Ijms 26 07456 g002
Ijms 26 07456 g003
Figure 3. Box plots showing the distribution of data on gestational age at delivery, neonatal weight, and placental weight by the time of ICP symptoms onset.
Figure 3. Box plots showing the distribution of data on gestational age at delivery, neonatal weight, and placental weight by the time of ICP symptoms onset.
Ijms 26 07456 g003
Ijms 26 07456 g004
Figure 4. ALT, AST and TBA serum levels between NR2B1 (RXRA) rs11381416 alleles in ICP women (ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBA, total bile acids).
Figure 4. ALT, AST and TBA serum levels between NR2B1 (RXRA) rs11381416 alleles in ICP women (ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBA, total bile acids).
Ijms 26 07456 g004
Ijms 26 07456 g005
Figure 5. The network of the genes we studied (CYP7A1, NR1H4, PPARA, RXRA) and their closest functional partners. The plot was from the STRING (Search Tool for the Retrieval of Interacting Genes) database (http://string-db.org/—accessed on 2 October 2024).
Figure 5. The network of the genes we studied (CYP7A1, NR1H4, PPARA, RXRA) and their closest functional partners. The plot was from the STRING (Search Tool for the Retrieval of Interacting Genes) database (http://string-db.org/—accessed on 2 October 2024).
Ijms 26 07456 g005
Table 1. Demographic and main clinical data of ICP patients and controls.
Table 1. Demographic and main clinical data of ICP patients and controls.
ParameterControls (N = 211)ICP (N = 96)p
Maternal age, (years) (mean ± SD)30.68 ± 4.6730.43 ± 4.240.648
<25, n (%)19 (9.00%)8 (8.33%)0.853
25–34, n (%)145 (68.72%)69 (71.88%)
≥35, n (%)47 (22.27%)19 (19.79%)
Systolic BP, mmHg (median (IQR))105 [105; 115]110 [100; 120]0.166
Diastolic BP, mmHg (median (IQR))70 [60; 70]70 [60; 75]0.206
Maternal pre-pregnancy BMI (kg/m2) (median (IQR))21.14 [19.63; 23.42]21.95 [20.37; 23.63]0.109
Underweight (<18.5)22 (10.43%)9 (9.38%)0.775
Normal weight (18.5 ≤ BMI < 25.0)161 (76.30%)70 (72.92%)
Overweight (25.0 ≤ BMI < 30)21 (9.95%)13 (13.54%)
Obesity (≥30)7 (3.32%)4 (4.17%)
Maternal BMI at delivery (kg/m2) (median (IQR))26.72 [24.64; 29.07]26.23 [23.95; 28.94]0.131
BMI Increase During Pregnancy (kg/m2) (median (IQR))5.21 [4.15; 6.52]4.11 [2.94; 5.02]<0.001
Gestational weight gain, n (%)
Inadequate52 (24.64%)40 (41.67%)0.010
Adequate87 (41.23%)32 (33.33%)
Excessive72 (34.12%)24 (25.00%)
Number of pregnancies, median (IQR)2 [1; 2]2 [1; 2]0.103
Gestational age at delivery (week), median (IQR)39 [38; 40]37 [36; 39]<0.001
Delivery, n (%)
Preterm < 37 week19 (9.00%)54 (56.25%)<0.001
Term ≥ 37 week192 (91.00%)42 (43.75%)
Type of delivery, n (%) 0.037
Operative69 (32.70)44 (45.83)
Vaginal142 (67.30)52 (54.17)
Newborn sex, n (%) 0.325
Female89 (42.18)47 (48.96)
Male122 (57.82)49 (51.04)
Newborn weight (g), (mean ± SD)3425.59 ± 433.823091.03 ± 634.81<0.001
Placenta weight (g), (mean ± SD)620.18 ± 111.37581.06 ± 150.630.053
TB (mg/dL), median [IQR]—0.475 [0.330; 0.720]—
ALT (IU/L), median [IQR]—227.50 [67.45; 399.45]—
AST (IU/L), median [IQR]—124.00 [51.05; 211.95]—
TBA (μmol/L), median [IQR]1.10 [0.50; 2.10]19.75 [14.93; 33.36]<0.001
ICP classification, n (%)— —
low (10 ≤ TBA < 40 μmol/L), 76 (79.17)
moderate (40 ≤ TBA < 100 μmol/L) 17 (17.71)
high (TBA ≥ 100 μmol/L) 3 (3.12)
Onset of ICP symptoms (week), median (IQR)—34.00 [30.00; 36.00]—
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; ICP, Intrahepatic cholestasis of pregnancy; TB, total bilirubin; TBA, total bile acids; gestational weight gain was calculated based on IOM recommendations (2009); ICP classification according to the guidelines of Royal College of Obstetricians and Gynaecologists (RCOG).
Table 2. Allelic distribution of SNVs in ICP patients and healthy women.
Table 2. Allelic distribution of SNVs in ICP patients and healthy women.
Gene/SNVAllelsControls (N = 422)ICP (N = 192)OR (95% CI)χ2p
NR1H4
rs56163822		G414 (0.981)187 (0.973)1.383 (0.446–4.286)0.3190.571
T8 (0.018)5 (0.026)
CYP7A1
rs3808607		G184 (0.436)101 (0.526)0.697 (0.495–0.981)4.2990.038
T238 (0.563)91 (0.473)
NR2B1
rs749759		G316 (0.748)139 (0.723)1.136 (0.773~1.671)0.4240.514
A106 (0.251)53 (0.276)
NR2B1
rs11381416		(-)392 (0.928)175 (0.911)1.269 (0.682~2.362)0.5680.450
A30 (0.071)17 (0.088)
PPARA
rs1800206		C397 (0.94)174 (0.906)1.642 (0.873~3.089)2.4120.120
G25 (0.059)18 (0.093)
Table 3. Association between single nucleotide variants and ICP risk under different genetic models.
Table 3. Association between single nucleotide variants and ICP risk under different genetic models.
Inheritance ModelGenotypesControls (N = 211)ICP (N = 96)OR (95% CI)pAIC
NR1H4 rs56163822
CodominantGG203 (96.2)91 (94.8)1.000.574385.1
GT8 (3.8)5 (5.2)1.39 (0.44–4.38)
TT0 (0.0)0 (0.0)—
log-Additive0, 1, 2211 (68.7)96 (31.3)1.39 (0.44–4.38)0.574385.1
CYP7A1 rs3808607
CodominantGG42 (19.9)30 (31.2)1.000.093382.7
GT100 (47.4)41 (42.7)0.57 (0.32–1.04)
TT69 (32.7)25 (26.0)0.51 (0.26–0.98)
DominantGT + TT169 (80.1)66 (68.8)0.55 (0.32–0.95)0.032380.9
RecessiveGG + GT142 (67.3)71 (74.0)0.72 (0.42–1.24)0.236384.0
OverdominantTT + GG111 (52.6)55 (57.3)1.21 (0.74–1.97)0.445384.9
log-Additive0, 1, 2211 (68.7)96 (31.3)0.71 (0.51–1.00)0.046381.4
NR2B1 rs749759
CodominantGG104 (53.1)48 (54.5)1.000.779357.1
AG78 (39.8)32 (36.4)0.89 (0.52–1.52)
AA14 (7.1)8 (9.1)1.24 (0.49–3.15)
DominantAG-AA92 (46.9)40 (45.5)0.94 (0.57–1.56)0.817355.5
RecessiveGG + AG182 (92.9)80 (90.9)1.30 (0.52–3.22)0.575355.3
OverdominantGG + AA118 (60.2)56 (63.6)0.86 (0.51–1.45)0.582355.3
log-Additive0, 1, 2196 (69.0)88 (31.0)1.01 (0.68–1.50)0.955355.6
NR2B1 rs11381416
Codominant-/-182 (86.3)81 (84.4)1.000.447385.8
-/A28 (13.3)13 (13.5)1.04 (0.51–2.12)
A/A1 (0.5)2 (2.1)4.49 (0.40–50.27)
Dominant-/A+ -/-29 (13.7)15 (15.6)1.16 (0.59–2.29)0.665385.3
RecessiveA/A + -/A210 (99.5)94 (97.9)4.47 (0.40–49.88)0.206383.8
OverdominantA/A + -/-183(86.7)83(86.5)1.02 (0.50 2.08)0.948385.4
log-Additive0, 1, 2211 (68.7)96 (31.3)1.25 (0.68–2.29)0.468384.9
PPARA rs1800206
CodominantCC187 (88.6)79 (82.3)1.000.323385.2
CG23 (10.9)16 (16.7)1.65 (0.83–3.28)
GG1 (0.5)1 (1.0)2.37 (0.15–38.32)
DominantCG + GG24 (11.4)17 (17.7)1.68 (0.85–3.29)0.138383.2
RecessiveCC + CG210 (99.5)95 (99.0)2.21 (0.14–35.72)0.581385.1
OverdominantCC + GG188 (89.1)80 (83.3)1.63 (0.82–3.26)0.168383.5
log-Additive0, 1, 2211 (68.7)96 (31.3)1.63 (0.87–3.05)0.134383.2
AIC, Akaike information criteria; ICP, Intrahepatic cholestasis of pregnancy; OR, odds ratio; 95% CI, 95% confidence interval. p < 0.05 was considered significant.
Table 4. Differences in liver function tests BA, ALT, and AST between subgroups distinguished by the time of ICP symptoms occurrence.
Table 4. Differences in liver function tests BA, ALT, and AST between subgroups distinguished by the time of ICP symptoms occurrence.
Parameter<28 Weeks
(N = 9)		28–36 Weeks
(N = 69)		≥37 Weeks
(N = 18)		p
ALT (IU/L), median [IQR]371.10 [249.75; 396.65]213.00 [78.10; 409.00]62.80 [17.70; 320.45]0.145
AST (IU/L), median [IQR]208.80 [114.60; 225.55]114.40 [57.90; 196.00]36.50 [25.55; 179.00]0.265
TBA (μmol/L), median [IQR]19.80 [15.00; 22.90]19.70 [14.86; 34.80]18.90 [15.00; 28.04]0.681
ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBA, total bile acids; p, Kruskal-Wallis rank sum test.
Table 5. Association between genotypes with median serum TBA, AST and ALT values in ICP women.
Table 5. Association between genotypes with median serum TBA, AST and ALT values in ICP women.
Gene/SNVGenotypesTBA (μmol/L)pALT (IU/L)pAST (IU/L)p
NR1H4
rs56163822		GG (N = 91)21.20 [15.00; 33.86]0.091237.10 [68.00; 400.20]0.132131.00 [52.00; 215.10]0.117
GA (N = 5)13.72 [12.10; 18.21] 59.85 [12.70; 107.00] 41.20 [14.40; 68.00]
AA (N = 0)— — —
CYP7A1
rs3808607		GG (N = 30)22.05 [12.81; 34.30]0.619271.00 [148.40; 414.90]0.130134.40 [85.30; 236.00]0.209
GT (N = 41)17.54 [14.86; 25.41] 156.50 [32.60; 318.00] 103.20 [28.95; 178.50]
TT (N = 25)21.20 [16.20; 28.40] 245.60 [78.10; 398.70] 123.45 [48.30; 303.40]
NR2B1
rs749759		GG (N = 53)22.30 [15.40; 33.30]0.623242.10 [68.00; 398.70]0.911132.00 [50.10; 215.10]0.982
GA (N = 33)17.60 [15.00; 24.97] 179.50 [63.50; 352.75] 108.00 [55.00; 187.05]
AA (N = 10)17.71 [11.49; 54.28] 265.95 [30.00; 427.30] 122.35 [28.00; 307.50]
NR2B1
rs11381416		-/- (N = 81)18.21 [14.86; 25.10]0.019213.00 [61.65; 382.10]0.060113.20 [48.10; 208.80]0.079
-/A ((N = 13)25.41 [22.00; 58.00] 277.60 [135.65; 403.00] 171.30 [72.00; 193.00]
A/A (N = 2)65.40 [34.30; 96.50] 529.20 [491.60; 566.80] 336.40 [319.00; 353.80]
PPARA
rs1800206		CC (N = 79)18.37 [14.30; 30.85]0.524239.20 [72.50; 399.45]0.239124.00 [53.10; 211.95]0.232
CG (N = 16)22.52 [16.35; 36.44] 118.55 [66.85; 249.20] 108.00 [51.05; 149.25]
GG (N = 1)24.80 [24.80; 24.80] 506.10 [506.10; 506.10] 419.40 [419.40; 419.40]
ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBA, total bile acids; Median (IQR).
Table 6. Characteristics of selected genes and variants.
Table 6. Characteristics of selected genes and variants.
Geners NumberPosition (GRCh38.p14)RegionAlleleAllele Frequency in Europe *
NR1H4rs56163822chr12:100493323Non Coding Transcript VariantG > TG = 0.98, T = 0.02
CYP7A1rs3808607chr8:585003652KB Upstream VariantG > TG = 0.43, T = 0.57
NR2B1rs749759chr9:134432806Intron VariantA > GA = 0.23, G = 0.77
NR2B1rs11381416chr9:134432216Intron Variant(-) > A(-) = 0.92, A = 0.08
PPARArs1800206chr22:46218377Missense Variant (p.Leu162Val)C > GC = 0.94, G = 0.06
SNV ID in database dbSNP; given name according to NCBI; * 1000Genomes Project.
Table 7. PCR primers and restriction enzymes used for SNV genotyping.
Table 7. PCR primers and restriction enzymes used for SNV genotyping.
GeneSNVPrimer SequencesRestriction Enzyme
NR1H4rs561638225′-GCATTCCCACAGTCACAAAC-3′
5′-TGAGGAAATGCCTAGATGATGA-3′		BseGI
CYP7A1rs38086075′-AATTAGCCATTTGTTCATTCTATTAG-3′
5′-AATGTTTTTCCCAGTTCTCTTTC-3′		Eco31I
NR2B1rs7497595′-ATAGGGCTTGCCTGCCTAGA-3′
5′-CTCCACCATAGCCCAAGTGA-3′		BstXI
NR2B1rs113814165′-GCCTCCTCCTGGCTGTACTT-3′
5′-CTCATGACAACTGCCTTGCT-3′		EcoO109I
PPARArs18002065′-AACAATAAGTGAGCAACAAAAAAG-3′
5′-CGTTGTGTGACATCCCGCCAGAAA-3′		BglI
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Piątek, K.; Kurzawińska, G.; Ożarowski, M.; Olbromski, P.J.; Kamiński, A.; Brązert, M.; Karpiński, T.M.; Markwitz, W.; Seremak-Mrozikiewicz, A. Polymorphic Variants of Selected Genes Regulating Bile Acid Homeostasis in Women with Intrahepatic Cholestasis of Pregnancy. Int. J. Mol. Sci. 2025, 26, 7456. https://doi.org/10.3390/ijms26157456

AMA Style

Piątek K, Kurzawińska G, Ożarowski M, Olbromski PJ, Kamiński A, Brązert M, Karpiński TM, Markwitz W, Seremak-Mrozikiewicz A. Polymorphic Variants of Selected Genes Regulating Bile Acid Homeostasis in Women with Intrahepatic Cholestasis of Pregnancy. International Journal of Molecular Sciences. 2025; 26(15):7456. https://doi.org/10.3390/ijms26157456

Chicago/Turabian Style

Piątek, Krzysztof, Grażyna Kurzawińska, Marcin Ożarowski, Piotr Józef Olbromski, Adam Kamiński, Maciej Brązert, Tomasz M. Karpiński, Wiesław Markwitz, and Agnieszka Seremak-Mrozikiewicz. 2025. "Polymorphic Variants of Selected Genes Regulating Bile Acid Homeostasis in Women with Intrahepatic Cholestasis of Pregnancy" International Journal of Molecular Sciences 26, no. 15: 7456. https://doi.org/10.3390/ijms26157456

APA Style

Piątek, K., Kurzawińska, G., Ożarowski, M., Olbromski, P. J., Kamiński, A., Brązert, M., Karpiński, T. M., Markwitz, W., & Seremak-Mrozikiewicz, A. (2025). Polymorphic Variants of Selected Genes Regulating Bile Acid Homeostasis in Women with Intrahepatic Cholestasis of Pregnancy. International Journal of Molecular Sciences, 26(15), 7456. https://doi.org/10.3390/ijms26157456

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop